a public good project by the
Synthesis
Company
of California

© 2026

Linli Li | doi.page

0 works0 citations0 h-index

Linli Li

Hebei Medical University(CN)Tianjin University(CN)Sichuan University(CN)Guangxi Normal University(CN)Third Hospital of Hebei Medical University(CN)Chengdu Institute of Biology(CN)

Publications by Year

Research Areas

Computational Drug Discovery Methods, Synthesis and biological activity, Analytical Chemistry and Chromatography, Cancer therapeutics and mechanisms, Epigenetics and DNA Methylation

Most-Cited Works

→ SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model(2021)444 cited
→ ID-Score: A New Empirical Scoring Function Based on a Comprehensive Set of Descriptors Related to Protein–Ligand Interactions(2013)184 cited
→ Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2(2008)112 cited
→ Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor(2022)95 cited
→ PocketFlow is a data-and-knowledge-driven structure-based molecular generative model(2024)82 cited
→ RASA: A Rapid Retrosynthesis-Based Scoring Method for the Assessment of Synthetic Accessibility of Drug-like Molecules(2011)80 cited

→ Structure-activity relationship studies of phenothiazine derivatives as a new class of ferroptosis inhibitors together with the therapeutic effect in an ischemic stroke model(2020)

72 cited

→ Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking(2011)72 cited

→ PhDD: A new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility(2010)68 cited

→ Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo(2013)67 cited